Related Experiment Video

Updated: Jun 6, 2025

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
08:18

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

27.8K

FOXD2-AS1 Binding to MYC Activates EGLN3 to Affect the Malignant Progression of Clear Cell Renal Cell Carcinoma

Zhigang Huang1, Bin Liu2, Xiaoju Li1

  • 1Urology Department, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.

Journal of Biochemical and Molecular Toxicology
|December 2, 2024
PubMed

Insights

Long noncoding RNA FOXD2-AS1 promotes clear cell renal cell carcinoma (ccRCC) progression by upregulating EGLN3 expression through MYC recruitment. This FOXD2-AS1/MYC/EGLN3 axis accelerates ccRCC cell proliferation, migration, and invasion.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Long noncoding RNAs (lncRNAs) play crucial roles in cancer, but their regulatory mechanisms remain unclear.
  • FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) is highly expressed in various cancers, including clear cell renal cell carcinoma (ccRCC).

Purpose of the Study:

  • To investigate the regulatory mechanism of FOXD2-AS1 in ccRCC.
  • To elucidate the influence of FOXD2-AS1 on ccRCC cell functions.
  • To provide insights into ccRCC treatment and prognosis.

Main Methods:

  • Differential expression and survival analyses to identify prognostic lncRNAs.
  • lncRNA-transcription factor-mRNA triplet prediction using lncMAP.
  • RNA immunoprecipitation, chromatin immunoprecipitation, and dual-luciferase reporter assays to verify molecular interactions.
  • In vitro cell function assays and in vivo mouse experiments for validation.

Main Results:

  • FOXD2-AS1 and Egl-9 family hypoxia-inducible factor 3 (EGLN3) expression are elevated in ccRCC.
  • FOXD2-AS1 promotes ccRCC cell proliferation, migration, and invasion by upregulating EGLN3.
  • FOXD2-AS1 recruits MYC to the EGLN3 promoter region, mediating its regulatory effect.
  • The FOXD2-AS1/MYC/EGLN3 axis accelerates ccRCC progression in vitro and in vivo.

Conclusions:

  • FOXD2-AS1 acts as a key oncogenic lncRNA in ccRCC.
  • The FOXD2-AS1/MYC/EGLN3 signaling pathway is a potential therapeutic target for ccRCC.
  • Understanding this axis offers a theoretical basis for refining ccRCC prognoses.
Keywords:
EGLN3FOXD2‐AS1MYCcell functionsclear cell renal cell carcinoma

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K